G1 Therapeutics buy bundfuture
Start price
29.11.20
/
50%
€12.08
Target price
€12.00
Performance (%)
31.37%
End price
13.12.20
€15.87
Summary
This prediction ended on 13.12.20 with a price of €15.87. The BUY prediction by bundfuture for G1 Therapeutics saw massive gains of 31.37%. bundfuture has 50% into this predictionG1 Therapeutics is a biopharmaceutical company that focuses on the discovery, development, and commercialization of small molecule therapeutics for the treatment of cancer. Their lead product candidate, Trilaciclib, is designed to improve the outcomes of chemotherapy by preserving hematopoietic stem cells and immune system function. G1 Therapeutics is also developing therapeutics for lung cancer, glioblastoma multiforme, and other solid tumors. The company went public in May 2017 and is listed on the NASDAQ exchange under the symbol GTHX.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| G1 Therapeutics | -5.852% | -5.852% | 60.893% | -80.865% |
| iShares Core DAX® | 2.594% | -1.158% | 14.782% | 16.813% |
| iShares Nasdaq 100 | 3.553% | -1.727% | 43.265% | 44.227% |
| iShares Nikkei 225® | 0.687% | -8.354% | 18.454% | 1.361% |
| iShares S&P 500 | 2.209% | -0.942% | 31.361% | 42.812% |